Login to Your Account



Micromet, Amgen $976M Deal is Love at First BiTE

By Catherine Shaffer


Tuesday, July 12, 2011
Amgen Inc. has joined a long list of pharma companies eager to capitalize on Micromet's BiTE antibody platform, which showed unusual promise in recent Phase II studies. The agreement tallies up to $976 million including an up-front payment of €10 million (US$14 million), plus milestones, royalties and development funding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription